Bharat Biotech: Covaxin is 77.8% effective, provides 65.2% protection against Delta variant

Phase-III trials of Covaxin, made by Hyderabad’s Bharat Biotech showed it was 93.4% effective against severe symptomatic Covid-19, the firm said on Saturday. The data demonstrated 65.2% protection against the Delta variant, first identified in India. The Delta variant had led to a surge in infections in April and May, and the world’s highest daily death tolls.Phase-III trials of Covaxin, made by Hyderabad’s Bharat Biotech showed it was 93.4% effective against severe symptomatic Covid-19, the firm said on Saturday. The data demonstrated 65.2% protection against the Delta variant, first identified in India. The Delta variant had led to a surge in infections in April and May, and the world’s highest daily death tolls.Read More

Leave a Reply

Your email address will not be published. Required fields are marked *